Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

    Get Diamond plan for FREE

    logo

    Alpha Tau Medical Ltd. (DRTSW)

    Price:

    0.35 USD

    ( - -0.02 USD)

    Your position:

    0 USD

    ACTION PANEL
    CREATE A NOTE
    ABOUT
    Symbol
    DRTSW
    Name
    Alpha Tau Medical Ltd.
    Industry
    Biotechnology
    Sector
    Healthcare
    Price
    0.350
    Market Cap
    29.839M
    Enterprise value
    215.587M
    Currency
    USD
    Ceo
    Uzi Sofer
    Full Time Employees
    125
    Ipo Date
    City
    Jerusalem
    Address
    Building B3

    Check the

    KEY TAKEAWAYS

    ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
    Descriptive alt text

    (REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION

    SIMILAR COMPANIES STI SCORE

    Similar STI Score

    Regeneron Pharmaceuticals, Inc.

    VALUE SCORE:

    6

    Symbol
    REGN
    Market Cap
    76.562B
    Industry
    Biotechnology
    Sector
    Healthcare

    2nd position

    ADMA Biologics, Inc.

    VALUE SCORE:

    11

    Symbol
    ADMA
    Market Cap
    4.706B
    Industry
    Biotechnology
    Sector
    Healthcare

    The best

    Genmab A/S

    VALUE SCORE:

    11

    Symbol
    GMAB
    Market Cap
    122.616B
    Industry
    Biotechnology
    Sector
    Healthcare
    FUNDAMENTALS
    P/E
    -10.572
    P/S
    0
    P/B
    5.446
    Debt/Equity
    0.174
    EV/FCF
    0
    Price to operating cash flow
    -1.000
    Price to free cash flow
    -1.000
    EV/sales
    0
    Earnings yield
    -0.095
    Debt/assets
    0.129
    FUNDAMENTALS
    Net debt/ebidta
    -0.296
    Interest coverage
    0
    Research And Developement To Revenue
    0
    Intangile to total assets
    0
    Capex to operating cash flow
    0
    Capex to revenue
    0
    Capex to depreciation
    0
    Return on tangible assets
    -0.382
    Debt to market cap
    0.031
    Piotroski Score
    1.000
    FUNDAMENTALS
    PEG
    1.295
    P/CF
    0
    P/FCF
    0
    RoA %
    -38.175
    RoIC %
    20.168
    Gross Profit Margin %
    0
    Quick Ratio
    8.433
    Current Ratio
    8.433
    Net Profit Margin %
    0
    Net-Net
    0.539
    FUNDAMENTALS PER SHARE
    FCF per share
    0
    Revenue per share
    0
    Net income per share
    -0.477
    Operating cash flow per share
    0
    Free cash flow per share
    0
    Cash per share
    0.862
    Book value per share
    0.926
    Tangible book value per share
    0.926
    Shareholders equity per share
    0.926
    Interest debt per share
    0.161
    TECHNICAL
    52 weeks high
    0.360
    52 weeks low
    0.325
    Current trading session High
    0.360
    Current trading session Low
    0.325
    DIVIDEND
    Dividend yield
    0.00%
    Payout ratio
    0.00%
    Years of div. Increase
    0
    Years of div.
    0
    Q-shift
    Dividend per share
    0
    SIMILAR COMPANIES
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -0.406
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -0.288
    logo

    Country
    IL
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -1.873
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -1.563
    logo

    Country
    IL
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -1.759
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -2.874
    logo

    Country
    IL
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -2.587
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -3.511
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -0.546
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -0.369
    DESCRIPTION

    Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma, lung, and prostate cancers. The company was founded in 2015 and is headquartered in Jerusalem, Israel.

    NEWS